Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF U.K. ERECTILE DYSFUNCTION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
4.3 VENDOR SHARE ANALYSIS
4.4 BRAND ANALYSIS
4.4.1 LEADING BRANDS
4.4.2 BRAND POSITIONING
4.4.3 MARKET PENETRATION
4.4.4 COMPETITIVE ANALYSIS
4.5 CONSUMER INSIGHTS
4.5.1 DEMOGRAPHIC INSIGHTS
4.5.2 PSYCHOGRAPHIC PROFILE
4.5.3 CONSUMER PREFERENCES
4.5.4 PURCHASING BEHAVIOUR
4.5.5 FACTORS INFLUENCING BUYING DECISION
4.6 PERFORMANCE ANALYSIS
4.6.1 TREND ANALYSIS
4.7 RETAIL ANALYSIS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISING PREVALENCE OF CHRONIC DISEASES
5.1.2 RISING ADOPTION OF SEDENTARY LIFESTYLE AND ASSOCIATED STRESS
5.1.3 RISING PRODUCT LAUNCHES BY MAJOR MARKET PLAYERS
5.1.4 RISING PATIENT AWARENESS REGARDING THE CONDITION AND MEDICATION
5.2 RESTRAINTS
5.2.1 REGULATORY CONSTRAINTS FOR APPROVAL
5.2.2 HIGH COST OF ERECTILE DYSFUNCTION TREATMENT
5.3 OPPORTUNITIES
5.3.1 AVAILABILITY OF PRESCRIPTION MEDICATION AND ITS GENERIC VERSION
5.3.2 RISING TECHNOLOGICAL ADVANCEMENTS
5.3.3 RISING RESEARCH AND DEVELOPMENT ACTIVITIES
5.4 CHALLENGES
5.4.1 VARIOUS SIDE EFFECTS ASSOCIATED WITH ERECTILE DYSFUNCTION DRUGS
5.4.2 LACK OF SKILLED PROFESSIONALS
6 U.K. ERECTILE DYSFUNCTION MARKET, BY PRODUCT TYPE
6.1 OVERVIEW
6.2 DRUGS
6.2.1 ORAL DRUGS
6.2.1.1 BRANDED
6.2.1.1.1 VIAGRA
6.2.1.1.2 CIALIS
6.2.1.1.3 LEVITRA
6.2.1.1.4 AVANAFIL
6.2.1.1.5 OTHERS
6.2.1.2 GENERIC
6.2.2 TOPICAL FORMULATION
6.2.3 PENILE INJECTIONS
6.2.3.1 PAPAVERINE
6.2.3.2 PHENTOLAMINE
6.2.3.3 PROSTAGLANDIN E1 (PGE1)
6.2.4 SUPPOSITORIES
6.3 DEVICES
6.3.1 PENIS PUMPS/VACCUM CONSTRICTION DEVICES
6.3.1.1 HAND-POWERED
6.3.1.2 BATTERY-POWERED PUMP
6.3.2 PENILE IMPLANTS
6.3.2.1 SEMIRIGID/MALLEABLE
6.3.2.2 INFLATABLE
6.3.3 SHOCK WAVE THERAPY
7 U.K. ERECTILE DYSFUNCTION MARKET, BY TYPE
7.1 OVERVIEW
7.2 SECONDARY ERECTILE DYSFUNCTION
7.3 PRIMARY ERECTILE DYSFUNCTION
8 U.K. ERECTILE DYSFUNCTION MARKET, BY AGE GROUP
8.1 OVERVIEW
8.2 LESS THAN 40
8.3 40-60
8.4 60 AND ABOVE
9 U.K. ERECTILE DYSFUNCTION MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 SPECIALTY CLINICS
9.4 HOME HEALTHCARE
9.5 AMBULATORY SURGICAL CENTERS
9.6 OTHERS
10 U.K. ERECTILE DYSFUNCTION MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 DIRECT TENDERS
10.3 HOSPITAL PHARMACY
10.4 RETAIL PHARMACY
10.5 ONLINE PHARMACY
10.6 OTHERS
11 U.K. ERECTILE DYSFUNCTION MARKET, COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: GLOBAL
12 SWOT ANALYSIS
13 COMPANY PROFILES
13.1 PFIZER INC.
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 PRODUCT PORTFOLIO
13.1.4 RECENT DEVELOPMENTS
13.2 LUPIN
13.2.1 COMPANY SNAPSHOT
13.2.2 REVENUE ANALYSIS
13.2.3 PRODUCT PORTFOLIO
13.2.4 RECENT DEVELOPMENTS
13.3 COLOPLAST CORP
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 PRODUCT PORTFOLIO
13.3.4 RECENT DEVELOPMENTS
13.4 VIATRIS INC.
13.4.1 COMPANY SNAPSHOT
13.4.2 REVENUE ANALYSIS
13.4.3 PRODUCT PORTFOLIO
13.4.4 RECENT DEVELOPMENTS
13.5 TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.5.1 COMPANY SNAPSHOT
13.5.2 REVENUE ANALYSIS
13.5.3 PRODUCT PORTFOLIO
13.5.4 RECENT DEVELOPMENTS
13.6 AUGUSTA MEDICAL SYSTEMS
13.6.1 COMPANY SNAPSHOT
13.6.2 PRODUCT PORTFOLIO
13.6.3 RECENT DEVELOPMENT
13.7 BAYER AG
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENTS
13.8 BOSTON SCIENTIFIC CORPORATION
13.8.1 COMPANY SNAPSHOT
13.8.2 REVENUE ANALYSIS
13.8.3 PRODUCT PORTFOLIO
13.8.4 RECENT DEVELOPMENTS
13.9 ELI LILY AND COMPANY
13.9.1 COMPANY SNAPSHOT
13.9.2 REVENUE ANALYSIS
13.9.3 PRODUCT PORTFOLIO
13.9.4 RECENT DEVELOPMENTS
13.1 RIGICON, INC.
13.10.1 COMPANY SNAPSHOT
13.10.2 PRODUCT PORTFOLIO
13.10.3 RECENT DEVELOPMENT
13.11 ZEPHYR SURGICAL IMPLANTS.
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 RECENT DEVELOPMENT
14 QUESTIONNAIRE
15 RELATED REPORTS
List of Table
TABLE 1 U.K. ERECTILE DYSFUNCTION MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 2 U.K. DRUGS IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 3 U.K. ORAL DRUGS IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 4 U.K. BRANDED IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 5 U.K. PENILE INJECTIONS IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 6 U.K. DEVICES IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 7 U.K. PENIS PUMPS/VACCUM CONSTRICTION DEVICES IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 8 U.K. PENILE IMPLANTS IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 9 U.K. ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 10 U.K. ERECTILE DYSFUNCTION MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 11 U.K. ERECTILE DYSFUNCTION MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 12 U.K. ERECTILE DYSFUNCTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
List of Figure
FIGURE 1 U.K. ERECTILE DYSFUNCTION MARKET: SEGMENTATION
FIGURE 2 U.K. ERECTILE DYSFUNCTION MARKET: DATA TRIANGULATION
FIGURE 3 U.K. ERECTILE DYSFUNCTION MARKET: DROC ANALYSIS
FIGURE 4 U.K. ERECTILE DYSFUNCTION MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 U.K. ERECTILE DYSFUNCTION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 U.K. ERECTILE DYSFUNCTION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 U.K. ERECTILE DYSFUNCTION MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 U.K. ERECTILE DYSFUNCTION MARKET: DBMR MARKET POSITION GRID
FIGURE 9 U.K. ERECTILE DYSFUNCTION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 U.K. ERECTILE DYSFUNCTION MARKET: SEGMENTATION
FIGURE 11 THE RISING RATES OF CHRONIC DISEASES AMONG MEN IS EXPECTED TO DRIVE THE GROWTH OF THE U.K. ERECTILE DYSFUNCTION MARKET FROM 2024 TO 2031
FIGURE 12 THE DRUGS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.K. ERECTILE DYSFUNCTION MARKET IN 2024 AND 2031
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF U.K ERECTILE DYSFUNCTION MARKET
FIGURE 14 U.K. ERECTILE DYSFUNCTION MARKET: BY PRODUCT TYPE, 2022
FIGURE 15 U.K. ERECTILE DYSFUNCTION MARKET: BY PRODUCT TYPE, 2024-2031 (USD MILLION)
FIGURE 16 U.K. ERECTILE DYSFUNCTION MARKET: BY PRODUCT TYPE, CAGR (2024-2031)
FIGURE 17 U.K. ERECTILE DYSFUNCTION MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 U.K. ERECTILE DYSFUNCTION MARKET: BY TYPE, 2022
FIGURE 19 U.K. ERECTILE DYSFUNCTION MARKET: BY TYPE, 2024-2031 (USD MILLION)
FIGURE 20 U.K. ERECTILE DYSFUNCTION MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 21 U.K. ERECTILE DYSFUNCTION MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 U.K. ERECTILE DYSFUNCTION MARKET: BY AGE GROUP, 2022
FIGURE 23 U.K. ERECTILE DYSFUNCTION MARKET: BY AGE GROUP, 2024-2031 (USD MILLION)
FIGURE 24 U.K. ERECTILE DYSFUNCTION MARKET: BY AGE GROUP, CAGR (2024-2031)
FIGURE 25 U.K. ERECTILE DYSFUNCTION MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 26 U.K. ERECTILE DYSFUNCTION MARKET: BY END USER, 2023
FIGURE 27 U.K. ERECTILE DYSFUNCTION MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 28 U.K. ERECTILE DYSFUNCTION MARKET: BY END USER, CAGR (2024-2031)
FIGURE 29 U.K. ERECTILE DYSFUNCTION MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 U.K. ERECTILE DYSFUNCTION MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 31 U.K. ERECTILE DYSFUNCTION MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 32 U.K. ERECTILE DYSFUNCTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 33 U.K. ERECTILE DYSFUNCTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 U.K. ERECTILE DYSFUNCTION MARKET: COMPANY SHARE 2023 (%)
